• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rallybio Corporation (Amendment)

    1/23/23 1:34:12 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email
    SC 13G/A 1 tm233716d1_sc13ga.htm SC 13G/A

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Rallybio Corp.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    75120L100

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 
     
      1. Names of Reporting Persons
    Tekla Capital Management LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,727,067
     
    7. Sole Dispositive Power
    1,727,067
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,727,067
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    4.6%
     
      12. Type of Reporting Person (See Instructions)
    IA, CO
               

     

    2

     

     

    CUSIP No. 
     
      1. Names of Reporting Persons
    Daniel R. Omstead
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,727,067
     
    7. Sole Dispositive Power
    1,727,067
     
    8. Shared Dispositive Power
    0
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,727,067
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    4.6%
     
      12. Type of Reporting Person (See Instructions)
    IN, HC
               

     

    3

     

     

    Item 1.
      (a) Name of Issuer
    Rallybio Corp.
      (b) Address of Issuer’s Principal Executive Offices
    234 Church Street, Suite 1020, New Haven, CT 06510
     
    Item 2.
      (a) Name of Person Filing
    Tekla Capital Management LLC
      (b) Address of Principal Business Office or, if none, Residence
    100 Federal Street, 19
    th Floor, Boston, MA 02110
      (c) Citizenship
    Delaware Corporation
      (d) Title of Class of Securities
    Common Stock
      (e) CUSIP Number
    75120L100
     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    4

     

     

    Item 4. Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned:
    1,727,067
      (b) Percent of class:
    4.6%
      (c) Number of shares as to which the person has:
     
        (i) Sole power to vote or to direct the vote
    0
        (ii) Shared power to vote or to direct the vote
    1,727,067
        (iii) Sole power to dispose or to direct the disposition of
    1,727,067
        (iv) Shared power to dispose or to direct the disposition of
    0
     
    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    See attached Exhibit A.
     
    Item 8. Identification and Classification of Members of the Group
    Not applicable.  
     
    Item 9. Notice of Dissolution of Group
    N/A

     

    5

     

     

    Item 10. Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signatures

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     Tekla Capital Management LLC
      

    Dated: January 23, 2023

    By:/s/ Laura Woodward
     Name/Title:Laura Woodward, Treasurer

     

     Daniel R. Omstead
      

    Dated: January 23, 2023

    By:

    /s/ Daniel R. Omstead

     Name:

    Daniel R. Omstead

     

    6

     

     

    Exhibit A

     

    Tekla Capital Management LLC (“TCM”), an investment adviser registered pursuant to Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of 1,727,067 shares (or 4.6%) of the Common Stock of Rallybio Corp. (the “Company”) as a result of acting as investment adviser to Tekla Healthcare Investors ("HQH"), Tekla Life Sciences Investors (“HQL”) and Tekla Healthcare Opportunities Fund (“THQ”), each of which is registered as an investment company pursuant to Section 8 of the Investment Company Act of 1940. Each of TCM and Daniel R. Omstead, through his control of TCM, has sole power to dispose of the 1,727,067 shares beneficially owned by HQH, HQL and THQ. Neither TCM nor Daniel R. Omstead has the sole power to vote or direct the vote of the shares beneficially owned by HQH, HQL and THQ, which power resides in each fund’s Board of Trustees. TCM carries out the voting of the shares under written guidelines established by each fund’s Board of Trustees.

     

    7

     

    Get the next $RLYB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rallybio Announces Reverse Stock Split of Common Stock

    Rallybio Corporation (NASDAQ:RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated Certificate of Incorporation (the "Amendment") to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is intended to give Rallybio greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Rallybio common stock to enable Rallybio to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Market. Pursuant to the Amendmen

    2/3/26 4:05:00 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

    – RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments. "In the third quarter, we continued to execute with discipline and focus, advancing our lead program, RLYB116, and achieving a key clinical milestone with the completion of dosing in Cohort 1 in our confirmatory PK/PD P

    11/6/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

    – Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 –    – Data Readouts for Completed Study Expected in 4Q 2025 – Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. "We are encouraged by the data generated to date in this confirmatory multiple ascending dos

    9/25/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    SEC Filings

    View All

    Rallybio Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Rallybio Corp (0001739410) (Filer)

    1/29/26 5:14:47 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Rallybio Corporation

    DEF 14A - Rallybio Corp (0001739410) (Filer)

    1/2/26 4:05:33 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Rallybio Corporation

    PRE 14A - Rallybio Corp (0001739410) (Filer)

    12/23/25 4:01:36 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rallybio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Rallybio from Buy to Neutral

    4/9/25 8:36:28 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by JP Morgan

    JP Morgan downgraded Rallybio from Overweight to Neutral

    5/15/24 7:39:44 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by Jefferies with a new price target

    Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

    2/7/24 6:42:56 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Boudreau Helen M

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:10:09 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chung Wendy

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:09:20 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunt Ronald

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:08:25 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    11/12/24 10:34:15 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rallybio Corporation

    SC 13G - Rallybio Corp (0001739410) (Subject)

    7/30/24 9:06:36 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    7/30/24 12:47:55 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Financials

    Live finance-specific insights

    View All

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

    -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

    12/20/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    View All

    Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

    -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

    6/29/23 7:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

    -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

    3/6/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

    1/31/23 4:05:00 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care